Cited by 397Cholinesterase and Neurodegenerative DiseasesAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 94 of the 101 references it cites were found in a registry or an index.

Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:

Open access

Grossberg, George T·2003·Current Therapeutic Research

DOI 10.1016/s0011-393x(03)00059-6PMC PMC4052996

Open this paper in CoChat — free account Open PDF

Abstract

Background Cholinesterase (ChE) inhibitors currently used in the treatment of Alzheimer's disease (AD) are the acetylcholinesterase (AChE)-selective inhibitors, donepezil and galantamine, and the dual AChE and butyrylcholinesterase (BuChE) inhibitor, rivastigmine. In addition to differences in selectivity for AChE and BuChE, ChE inhibitors also differ in pharmacokinetic and pharmacodynamic properties, and these differences could significantly impact on safety, tolerability, and efficacy.Objective The aim of this article was to provide an overview of the ChE inhibitors widely used in AD, focusing on key pharmacologic differences among agents and how these may translate into important differences in safety, tolerability, and efficacy in clinical practice.Methods Using published literature collected over time by the author, a review was conducted, focusing on the pharmacology and clinical data of donepezil, galantamine, and rivastigmine.Results All ChE inhibitors have the potential to induce centrally mediated cholinergic adverse events (AEs), such as nausea and vomiting, if the dose is increased too rapidly or in increments that are too large. These AEs, which are most likely to occur during the "getting on," or dose-escalation, phase of treatment, may result in patients discontinuing treatment early without achieving optimum therapeutic benefit. To reduce the incidence of these AEs, a slow dose-escalation schedule has been established in clinical practice, consisting of a "start low, go slow" procedure with a minimum of 4 weeks between dose increases. After "getting on" treatment, maintaining treatment in the long term, or "staying on," may be achieved with good safety, tolerability, and sustained symptomatic efficacy across the key symptom domains (activities of daily living, behavior, and cognition).Conclusions ChE inhibitors provide symptomatic benefit in AD across key symptom domains. Factors influencing the safety, tolerability, and efficacy of these agents in clinical practice include ChE enzymes inhibited, brain and brain-region ChE selectivity, and metabolism route. Class-specific cholinergic AEs can be minimized using slow, flexible dose escalation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0011-393x(03)00059-6

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
J Neuropsychiatry Clin Neurosci
Yudofsky, S. C., & Hales, R. E. (1992) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.4.4.359 · Cited by 3,818
Physicians Desk Reference
Arky, R. A. (1994) · Cited by 2,632
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Molecular and cellular biology of cholinesterases
Massoulié, J., Pezzementi, L., Bon, S., Krejci, E., & Vallette, F.-M. (1993) · Progress in Neurobiology · doi:10.1016/0301-0082(93)90040-y · Cited by 1,214
Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study
McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., & Spiegel, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03399-7 · Cited by 1,182
Acetylcholinesterase Accelerates Assembly of Amyloid-β-Peptides into Alzheimer's Fibrils: Possible Role of the Peripheral Site of the Enzyme
Inestrosa, N. C., Alvarez, A. R., Pérez, C. A., Moreno, R. D., Vicente, M., Linker, C., Casanueva, O. I., Soto, C. A., & Garrido, J. (1996) · Neuron · doi:10.1016/s0896-6273(00)80108-7 · Cited by 1,117

Show all 101 references

Research works printed but not linked: 10

McRae, 1999, A large-scale, open-label trial of donepezil in the treatment of Alzheimer's disease: Side effects and concomitant medication use, Int J Neuropharmacol, 2, S176
Shua-Haim, 2001, Safety and tolerability of slow titration of rivastigmine (Exelon) in the treatment of patients with Alzheimer's disease (AD): An overall analysis of two prospective studies, J Am Geriatr Soc, 49, S76
Vellas, 1998, Interim results from an international clinical trial with rivastigmine evaluating a 2-week titration rate in mild to severe Alzheimer's disease patients, Int J Geriatr Psychopharmacol, 1, 140
Schneider, 1998, Systematic review of efficacy of rivastigmine for patients with Alzheimer's disease, Int J Geriatr Psychopharmacol, 1, S26
Anand, 2000, Dose-response effect of rivastigmine in the treatment of Alzheimer's disease, Int J Geriatr Psychopharmacol, 2, 68
Cummings, 2000, Rivastigmine provides behavioural benefits to Alzheimer's disease patients residing in a nursing home: Findings from a 26-week trial, Neurology, 54, A468
Sanders, 2001, Donepezil in dementia with Lewy bodies: Treatment and withdrawal, Int Psychogeriatr, 13, 224
Raskind M, Truyen L. Galantamine has long-term cognitive benefits in Alzheimer's disease—an analysis of responder rates at 36 months. Poster presented at the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy; April 3–6, 2003; Geneva, Switzerland.
Grossberg, 2001, Rivastigmine in Alzheimer's disease: Efficacy over 2 years compared with historical controls, Int Psychogeriatr, 13, 237
Barber, 1996, Butyrylcholinesterase alters the aggregation state of Aβ amyloid, Proc Soc Neurosci, 22, 1172

Sorted by citations

Items 201–300 of 397

Pharmacophore mapping of the crucial mediators of acetylcholinesterase and butyrylcholinesterase dual inhibition in Alzheimer's disease
Adeowo, F. Y., El-Rashedy, A. A. E., Ejalonibu, M. A., Lawal, I. A., Lawal, M. M., & Kumalo, H. M. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10377-w · Cited by 13
Medicinal perspectives, molecular docking and structure activity relationship of benzothiazole derived thiazole-based bis-benzohydrazide as potential anti-Alzheimer agents
Khan, S. A., Dera, A. A., Hussain, R., Iqbal, T., Khan, Y., Ahmad, Z., Ullah, F., & Hussain, A. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101742 · Cited by 10
Enzyme ChE, cholinergic therapy and molecular docking: Significant considerations and future perspectives
Jovičić, S. M. (2024) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320241289013 · Cited by 12
Reactive Oxygen Species, a Potential Therapeutic Target for Vascular Dementia
White, A. L., Talkington, G. M., Ouvrier, B., Ismael, S., Solch-Ottaiano, R. J., & Bix, G. J. (2024) · Biomolecules · doi:10.3390/biom15010006 · Cited by 11
Tangeretin offers neuroprotection against colchicine-induced memory impairment in Wistar rats by modulating the antioxidant milieu, inflammatory mediators and oxidative stress in the brain tissue
Ogunro, O. B., Karigidi, M. E., Gyebi, G. A., Turkistani, A. A., & Almehmadi, A. H. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-04769-2 · Cited by 10
Playing Around the Coumarin Core in the Discovery of Multimodal Compounds Directed at Alzheimer’s-Related Targets: A Recent Literature Overview
Rullo, M., Spada, G. L., Stefanachi, A., Macchia, E., Pisani, L., & Leonetti, F. (2025) · Molecules · doi:10.3390/molecules30040891 · Cited by 11
Biologics as Therapeutical Agents Under Perspective Clinical Studies for Alzheimer’s Disease
Li, H., Shen, X., Zhang, B., & Zhu, Z. (2025) · Molecules · doi:10.3390/molecules30173479 · Cited by 11
The Influence of Selected Antipsychotic Drugs on Biochemical Aspects of Alzheimer’s Disease
Podsiedlik, M., Markowicz-Piasecka, M., & Sikora, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094621 · Cited by 11
Amelioration of Scopolamine-Induced Cognitive Dysfunction in Experimental Mice Using the Medicinal Plant Salvia moorcroftiana
Wahid, F., Jan, T., Al-Joufi, F. A., Ali Shah, S. W., Nisar, M., & Zahoor, M. (2022) · Brain Sciences · doi:10.3390/brainsci12070894 · Cited by 10
Systematic formulation development of once-a-day gastroretentive controlled release tablets of rivastigmine using optimized polymer blends
Kapil, R., Dhawan, S., Singh, B., Garg, B., & Singh, B. (2012) · Journal of Drug Delivery Science and Technology · doi:10.1016/s1773-2247(12)50090-0 · Cited by 9
A Stability Indicating HPLC Assay Method for Analysis of Rivastigmine Hydrogen Tartrate in Dual-Ligand Nanoparticle Formulation Matrices and Cell Transport Medium
Huda, N. H., Gauri, B., Benson, H. A., & Chen, Y. (2018) · Journal of Analytical Methods in Chemistry · doi:10.1155/2018/1841937 · Cited by 9
Beyond Conventional Therapies: Molecular Dynamics of Alzheimer's Treatment through CLOCK/BMAL1 Interactions
Haskologlu, I. C., Erdağ, E., Şehirli, A. Ö., Uludağ, M. O., & Abacıoğlu, N. (2023) · Current Alzheimer Research · doi:10.2174/0115672050301014240315065235 · Cited by 8
Chemical composition, antioxidant, and enzyme inhibition activities of Crithmum maritimum essential oils: the first chemo-biological study for species grown in North Africa
Ismail, A., Elshibani, F. A., Mohammed, H. A., Al-Najjar, B. O., Korkor, A. M., Abdulkarim, A. K., Said, R. R., Almahmoud, S. A., & Sulaiman, G. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-74544-9 · Cited by 8
Ethyl α-D-glucopyranoside the first report in rice and its inhibitor for acetylcholinesterase by in vitro, in silico and fluorescence analysis
Sansenya, S., Mansalai, P., Payaka, A., Puttasoon, C., Buddhakala, N., Kongdin, M., & Chumanee, S. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.106641 · Cited by 8
Exploring multitarget potential of Piper nigrum fruit constituents for Alzheimer's disease: An AI-driven strategy
Bhanukiran, K., & Priya, V., V (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156108 · Cited by 8
A biguanide derivative and its cyclic anologue: Structural chracterization, AChE inhibitory effect and docking studies
Güngör, Ö., Köse, M., & Taşkın‐Tok, T. (2019) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2019.06.104 · Cited by 8
Computationally Elucidating the Binding Kinetics for Different AChE Inhibitors to Access the Rationale for Improving the Drug Efficacy.
Bai, F., & Jiang, H.-L. (2022) · Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.2c03632 · Cited by 7
Lycopodiastrum casuarinoides: An overview of their phytochemicals, biological activities, structure-activity relationship, biosynthetic pathway and 13C NMR data
Liu, Y., Wang, Q., Xie, Z., Zheng, D., Li, J., & Tan, G. (2023) · Fitoterapia · doi:10.1016/j.fitote.2022.105425 · Cited by 8
Current Advances in the Synthesis and Biological Evaluation of Pharmacologically Relevant 1,2,4,5-Tetrasubstituted-1H-Imidazole Derivatives
Rossi, R., & Ciofalo, M. (2019) · Current Organic Chemistry · doi:10.2174/1385272823666191014154129 · Cited by 8
Synthesis of dammarenolic acid derivatives with a potent α-glucosidase inhibitory activity
Smirnova, I. E., Petrova, A. V., Kazakova, O. B., Minnibaeva, E. M., Fedorova, A. A., Van, L. T., Van, C. T., Thi, N. P., Phuong, T. T. T., Thi, D. N., et al. (2019) · Medicinal Chemistry Research · doi:10.1007/s00044-019-02462-x · Cited by 8
Letter to the editor: Donepezil-induced parkinsonism in end-stage renal disease
Wang, H.-M., Liou, L., Hsu, C., & Lin, H. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05522-6 · Cited by 8
Exploring Potential of Nano-formulations in the Treatment of Alzheimer’s Disease through Nasal Route
Tekade, A. R., Kadam, P. V., Jagdale, S. K., Surwade, S., Gaikwad, A., Pawar, P., & Shinde, R. (2024) · Current Alzheimer Research · doi:10.2174/0115672050290462240222092303 · Cited by 8
Bioavailability Study of a Transdermal Patch Formulation of Rivastigmine Compared with Exelon in Healthy Subjects
Morte, A., Vaqué, A., Iniesta, M., Schug, B. S., Koch, C., de la Torre, R., & Schurad, B. (2022) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-022-00778-5 · Cited by 7
Orthosiphon aristatus (Blume) Miq. Extracts attenuate Alzheimer-like pathology through anti-inflammatory, anti-oxidative, and β-amyloid inhibitory activities
Chiang, K., Cheng, T., Kan, W., Wang, H., Li, J.-C., Cai, Y.-L., Cheng, C.-H., Liu, Y., Chang, C., & Chuu, J. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117132 · Cited by 9
Drug Design for Alzheimer’s Disease: Biologics vs. Small Molecules
Weaver, D. F. (2023) · Current Alzheimer Research · doi:10.2174/0115672050301583240307114452 · Cited by 7
Unveiling of Indanone‐Benzimidazole Hybrids as Anti‐Alzheimer's Agents: Computational and Experimental Studies
Kushwaha, P., Das, B., & Kumar, R. (2024) · ChemistrySelect · doi:10.1002/slct.202400275 · Cited by 7
Exploring Cannabis sativa L for Anti-Alzheimer Potential: An Extensive Computational Study including Molecular Docking, Molecular Dynamics, and ADMET Assessments
Nour, H., Yamari, I., Abchır, O., Mounadi, N., Samadi, A., Belaıdı, S., & Chtita, S. (2024) · Medicinal Chemistry · doi:10.2174/0115734064318657240822064240 · Cited by 12
Medial septal cholinergic neurotransmission is essential for social memory in mice
Shivakumar, A. B., Mehak, S. F., Gupta, A., & Gangadharan, G. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111207 · Cited by 9
Movement disorders associated with acetylcholinesterase inhibitors in Alzheimer’s dementia: A systematic review
Rissardo, J. P., & Caprara, A. L. F. (2025) · Brain Circulation · doi:10.4103/bc.bc_134_24 · Cited by 7
Characterization of rotenoid stemonal by semiempirical methods and molecular docking
de Oliveira, V. M., Estácio, S. P., Mendes, F. R. D. S., Campos, O. S., Marinho, M. M., & Marinho, E. S. (2020) · SN Applied Sciences · doi:10.1007/s42452-020-2346-7 · Cited by 7
Synthesis, Molecular Docking, and Biological Evaluation of Benzimidazole Derivatives as Selective Butyrylcholinesterase Inhibitors
Ha, Z. Y., Ong, H. C., Oo, C. W., & Yeong, K. Y. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210218151228 · Cited by 7
Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia
Masurkar, P. P., Chatterjee, S., Sherer, J. T., & Aparasu, R. R. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00863-5 · Cited by 7
Synthesis of N′-(4-/3-/2-/Non-substituted benzylidene)-4-[(4-methylphenyl)sulfonyloxy] Benzohydrazides and Evaluation of Their Inhibitory Activities against Monoamine Oxidases and β-Secretase
Sellitepe, H. E., Oh, J., Doğan, İ. S., Yıldırım, S., Aksel, A. B., Jeong, G. S., Khames, A., Abdelgawad, M. A., Gambacorta, N., Nicolotti, O., et al. (2021) · Applied Sciences · doi:10.3390/app11135830 · Cited by 7
Acetylcholinesterase Inhibitory Activity of Modified Lupane, Oleanane, and Ursane A‐seco‐Triterpenoids
Petrova, A. V., Kazakova, O. B., Nazarov, I. S., Csük, R., & Heise, N. V. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202300185 · Cited by 7
Enzyme Kinetics and Molecular Docking Investigation of Acetylcholinesterase and Butyrylcholinesterase Inhibitors from the Marine Alga Ecklonia cava
Park, S., Kim, Y. H., & Yang, S. Y. (2023) · Natural Product Sciences · doi:10.20307/nps.2023.29.3.182 · Cited by 7
Energy-efficient Approach to Multicomponent Reaction for the Synthesis of Therapeutically Relevant Heterocycles
Roy, R., -, R. K., Ansari, M. N., Deshmukh, G. S., Rai, A. K., Tripathi, G., & Kumar, A. (2023) · Current Organic Chemistry · doi:10.2174/0113852728264863231017071522 · Cited by 7
Determination of antioxidant, anticholinesterase, tyrosinase inhibitory activities and fatty acid profiles of 10 anatolian Klasea cass. species
Tel‐Çayan, G., Doğan, B., Erol, E., Öztürk, M., Nadeem, S., Ullah, Z., Duru, M. E., & Duran, A. (2015) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 7
A facile tandem double-dehydrative-double-Heck olefination strategy for pot-economic synthesis of ( E )-distyrylbenzenes as multi-target-directed ligands against Alzheimer's disease employing C. elegans model
Andhare, N. H., Thopate, Y., Shamsuzzama, S., Kumar, L., Sharma, T., Siddiqi, M. I., Sinha, A. K., & Nazir, A. (2018) · Tetrahedron · doi:10.1016/j.tet.2018.02.026 · Cited by 7
Translation from Preclinical Research to Clinical Trials: Transdermal Drug Delivery for Neurodegenerative and Mental Disorders
Nguyen‐Thi, P., Vo, T. K., Le, H. T., Nguyen, N. T. T., Nguyen, T. T., & Giau, V. V. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03718-x · Cited by 6
Smart Nanomedicines for Neurodegenerative Diseases: Empowering New Therapies with Molecular Imaging and Artificial Intelligence
Jeevanandam, J., Tsenov, G., Danquah, M. K., Ruiz‐Molina, D., Boussios, S., & Ovsepian, S. V. (2025) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-025-00813-6 · Cited by 6
Evaluation of pyrimidine-based compounds as AChE and BChE inhibitors: in vitro inhibition, molecular modeling, and statistical evaluation
Alım, Z., & Demir, Y. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05347-0 · Cited by 6
Morphological classification and changes in dementia (Review)
Tudor, A., Vasile, A., Trifu, S. C., & Cristea, M. B. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10955 · Cited by 7
Antibacterial, antioxidant, anti-cholinesterase potential and flavonol glycosides of Biscutella raphanifolia (Brassicaceae)
Boudouda, H. B. (2015) · Pakistan Journal of Pharmaceutical Sciences · doi:10.36721/pjps/28/1/01.01.2015/2626/153-158 · Cited by 6
Synthesis, Characterization, Biological Properties, and Sensor Applications of Novel Thiosemicarbazone Derivatives
Gezegen, H., Özbek, O., Topal, M., Şahin, H., & Koçyiğit, Ü. M. (2025) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.70001 · Cited by 5
Stem cell therapy offers new hope for the treatment of Alzheimer’s disease
He, G., Huang, J., Zeng, Z., Sun, H., Wu, C., Xu, Q., Hu, C., Jin, B., Tong, M., & Wang, C. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1650885 · Cited by 7
The cytotoxic, antioxidant, and anticholinesterase activity of steviol and isosteviol analogues, together with structure-activity relationships and molecular docking studies
Wisal, A., Ullah, A., Khan, B., Sıcak, Y., Öztürk, M., Muhammad, A., Anwar, W., Begum, S., Zafar, S., de Carvalho, P. V. S. D., et al. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.143049 · Cited by 5
Bioactive chemicals in Helianthus tuberosus L may reduce beta-amyloid cytotoxicity as a potential novel treatment for Alzheimer's disease
Zhu, W. M., Cadet, P., & Neuwirth, L. S. (2023) · Studies in natural products chemistry · doi:10.1016/b978-0-323-91294-5.00004-x · Cited by 5
Ameliorative Effect of Galantamine on Doxorubicin-Induced Cardiotoxicity and Hypothyroidism
Aldubayan, M. A. (2023) · International Journal of Pharmacology · doi:10.3923/ijp.2023.542.547 · Cited by 5
Cholinergic Crisis with Normal Serum Cholinesterase Levels due to Excessive Galantamine Ingestion: A Case Report
Suzuki, A., Mayahara, T., Katayama, T., Arai, H., Matsuura, K., Nagata, K., & Maruo, E. (2024) · JMA Journal · doi:10.31662/jmaj.2023-0170 · Cited by 5
Neuroprotective effects of phlorotannins: Biochemical and molecular mechanisms of antineuroinflammatory activities and memory-enhancing effects
Olasehinde, T. A., Olisah, C., & Olaniran, A. O. (2024) · Studies in natural products chemistry · doi:10.1016/b978-0-443-15628-1.00004-0 · Cited by 5
In vitro and in silico approach for the evaluation of enzyme inhibitory potential of Kadipatta (Murraya koenigii) collected from western Nepal
Pradhan, S. P., Subedi, I., Adhikari, K., Ashok, G. C., Pradhan, S. P., Aryal, M. R., Ghimire, G. P., & Pandey, B. P. (2024) · Clinical Traditional Medicine and Pharmacology · doi:10.1016/j.ctmp.2024.200161 · Cited by 5
Chemo‐Biocatalytic Oxidative Condensation of Natural Arylpropene with 2‐Aminobenzothiazole into Schiff‐Bases as Potent Anti‐Amyloid Agents: Studies Employing Transgenic C. elegans
Saima, S., Kumar, L., Lavekar, A. G., Sharma, T., Shamsuzzama, S., Equbal, D., Siddiqi, M. I., Sinha, A. K., & Nazir, A. (2018) · ChemistrySelect · doi:10.1002/slct.201800243 · Cited by 5
Observation of quantum signature in rivastigmine chemical bond break-up and quantum energetics, spectral studies of anti-Alzheimer inhibitors
Ali, M. R., & Mezei, M. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1708462 · Cited by 5
Effects of Gentiana delavayi Flower Extract on APP Processing in APP/PS1 CHO Cells
Yang, M., Zhou, K., Li, F., Yang, H., Yin, M., Zhang, L.-H., & Wang, F. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-00720 · Cited by 5
Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort Study
Rege, S., Carnahan, R. M., Johnson, M. L., Chen, H., Holmes, H. M., & Aparasu, R. R. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00851-9 · Cited by 5
Molecular docking and molecular dynamics approach to identify potential compounds in Huperzia squarrosa for treating Alzheimer’s disease
Tùng, B. T., Hang, T. T. T., Kim, N. B., Nhung, N. H., Linh, V. K., & Thu, D. K. (2022) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2021-0462 · Cited by 5
The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by methylene violet 3RAX
Önder, S., Biberoğlu, K., & Tacal, Ö. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.108845 · Cited by 5
Protective Factors for the Well-Being in Caregivers of Patients with Alzheimer’s: The Role of Relational Quality
Gozzoli, C., Giorgi, A., & D’Angelo, C. (2013) · Psychology · doi:10.4236/psych.2013.46a1009 · Cited by 5
Acetylcholinesterase inhibitors used or tested in Alzheimers disease therapy; their passive diffusion through blood brain barrier: In vitro study
Karasova, Z. (2013) · African Journal of Pharmacy and Pharmacology · doi:10.5897/ajpp2013.2977 · Cited by 5
Highly accurate disease diagnosis and highly reproducible biomarker identification with PathFormerPreprint
Li, F., Dong, Z., Zhao, Q., Payne, P., Province, M. A., Cruchaga, C., Zhang, M., Zhao, T., & Chen, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-3576068/v1 · Cited by 6
Cyclohexane-1,3-dione derivatives: Versatile precursors for total synthesis of natural products
Sharma, D., Kumar, M., Kumar, S., Mehta, M., & Das, P. (2024) · Tetrahedron · doi:10.1016/j.tet.2024.134395 · Cited by 4
A Review on the Pathophysiology of Alzheimer’s Disease
Agarwal, U., Kapoor, G. T., & Tonk, R. K. (2025) · Current Protein and Peptide Science · doi:10.2174/0113892037416859250915091846 · Cited by 5
Neuroprotective Role of Piperine-Encapsulated Casein Micelles in Mitigating Intracellular Dyshomeostasis in Alzheimer’s Disease Pathology
Mishra, J., Singh, C., & Bhatti, J. S. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05297-3 · Cited by 4
From brain waves to heartbeats: Exploring the combined role of electroencephalography and heart-rate variability in Alzheimer's disease diagnosis and management
Botchway, B. O. A., Kousiappa, I., Koupparis, A. M., Papacostas, S., Georgiades, S., Bashiardes, S., Hadjisavvas, A., Loucaides, G., Adamou, A., Christou, Y. P., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261428636 · Cited by 5
Assessing the potential of Psidium guajava derived phytoconstituents as anticholinesterase inhibitor to combat Alzheimer’s disease: an in-silico and in-vitro approach
Bhattacharya, K., Bhattacharjee, A., & Chakraborty, M. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2301930 · Cited by 4
RETRACTED ARTICLE: Metal free cross-dehydrogenative N-N coupling of primary amides with Lewis basic amines
Kathiravan, S., Dhillon, P., Zhang, T., & Nicholls, I. A. (2024) · Nature Communications · doi:10.1038/s41467-024-46890-9 · Cited by 4
Retracted
An Insight into Medicinal Chemistry and SAR Studies of Cholinesterase and BACE-1 Inhibitors for Alzheimer's Disease
Shome, A., Jha, K. T., Chahat, Chawla, V., & Chawla, P. A. (2024) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273315191241002115155 · Cited by 4
Enhanced delivery of rivastigmine for Alzheimer's disease: Convolvulus pluricaulis lipid hybrid nanoparticles
Garg, T., Patel, S., Yadav, D., Dave, V., & Yadav, R. (2024) · Nano-Structures & Nano-Objects · doi:10.1016/j.nanoso.2024.101406 · Cited by 4
Exploration of novel triazolo-thiadiazine hybrids of deferasirox as multi-target-directed anti-neuroinflammatory agents with structure–activity relationship (SAR): a new treatment opportunity for Alzheimer's disease
Shakir, S. A., Rashid, U., Marryum, Fatima, N., Ejaz, S. A., Fayyaz, A., Ullah, M. Z., Saeed, A., Khan, A., Al‐Harrasi, A., et al. (2025) · RSC Advances · doi:10.1039/d4ra06916a · Cited by 4
Influence of Rivastigmine transdermal on butyrylcholinesterase levels in patients with Alzheimer's disease
dos Santos, G. A. A., Canineu, P. R., Gonçalves, I. D., & Pardi, P. C. (2011) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642011dn05040012 · Cited by 4
The Effects of Aqueous Leave Extract of Moringa oleifera on the Hippocamppal Histology of Aluminium Chloride-Induced Alzheimer’s Disease in Adult Wistar Rats
Ozor, I. I., Agwag, Z. N., Finbarrs-Bello, E., Ozioko, O. M., Ozioko, U. S., & Iruka, N. C. (2020) · International Journal of Neurologic Physical Therapy · doi:10.11648/j.ijnpt.20200602.12 · Cited by 4
Nanoparticles encapsulating sesame seeds (Sesamum indicum) oil: Physicochemical, antioxidant and enzymatic inhibition properties
Lammari, N., Louaer, M., Louaer, O., Bensouıcı, C., Zermane, A., Elaı̈ssari, A., & Meniai, A. H. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.104003 · Cited by 4
The anti-Alzheimer compounds from tempeh oil in LPS-induced neuronal Schwann cells
Limanjaya, E. C., Subali, D., & Yanti, Y. (2022) · Journal of Ethnic Foods · doi:10.1186/s42779-022-00163-2 · Cited by 4
Synthesis of phenylethanoid glycosides from acrylic esters of glucose and aryldiazonium salts via palladium-catalyzed cross-coupling reactions and evaluation of their anti-Alzheimer activity
Narayanan, A. C., Venkatesh, R., Singh, S., Singh, G., Modi, G. P., Singh, S., & Kandasamy, J. (2023) · Carbohydrate Research · doi:10.1016/j.carres.2023.108920 · Cited by 4
Therapy of vascular dementia: perspectives and milestones
Moretti, R., Torre, P., Antonello, R. M., & Cazzato, G. (2005) · Therapy · doi:10.1586/14750708.2.4.649 · Cited by 4
Impact of cooking and conservation for twelve days on total polyphenols content, antioxidant and anticholinesterase activities of red onion
Laib, I., & Barkat, M. (2016) · African Journal of Pharmacy and Pharmacology · doi:10.5897/ajpp2015.4519 · Cited by 4
Improved Oral Bioavailability and Brain Distribution of Hesperidin via Cochleate Formulation: Statistical Optimization and Pharmacokinetic Study
Kaur, K., Kulkarni, Y. A., & Wairkar, S. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03297-z · Cited by 5
Therapeutic potential of Oxalis corniculata in circumventing Alzheimer's disease through in vitro and in silico investigations
Yadav, V., Das, S., Murmu, A., Matore, B. W., Satpathy, S., Mandal, V., Roy, P. P., Singh, J., & Patra, A. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121178 · Cited by 3
β-Alanine Is an Unexploited Neurotransmitter in the Pathogenesis and Treatment of Alzheimer’s Disease
Wozniczka, C. M., & Weaver, D. F. (2026) · NeuroSci · doi:10.3390/neurosci7010013 · Cited by 3
Neurocognitive Disorders
Ramalingam, J., Mohan, A., & Sachdev, P. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-15401-0_13 · Cited by 4
Marine-derived Compounds: A Powerful Platform for the Treatment of Alzheimer’s Disease
Arora, R., Babbar, R., Dabra, A., Chopra, B., Deswal, G., & Grewal, A. S. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249269050231129103002 · Cited by 3
Cholinesterase Inhibitory Compounds from Peltophorum Pterocarpum Flowers
Monehin, J. A., Oriola, A. O., Olawuni, I. J., Odediran, S. A., Ige, O. O., Idowu, T. O., & Ogundaini, A. O. (2024) · Chemistry Africa · doi:10.1007/s42250-024-00896-4 · Cited by 3
Blood-based therapies to combat neurodegenerative diseases
Jy, L., Lim, M. C. X., Koh, R. Y., Tsen, M. T., & Chye, S. M. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01368-x · Cited by 3
Effect of acetylcholinesterase inhibition on immune cells in the murine intestinal mucosa
Al-Mansori, A., Al-Sbiei, A., Bashir, G. H., Qureshi, M. M., Tariq, S., Altahrawi, A., al-Ramadi, B. K., & Fernández-Cabezudo, M. J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33849 · Cited by 2
Synthesis and cholinesterases inhibitory effects of water soluble zinc(II) and silicon(IV) phthalocyanines bearing ({8‐[3‐(dimethylamino)phenoxy]octyl}oxy) groups
Usta, B., Seyhan, G., Akkaya, D., Barut, B., Bıyıklıoğlu, Z., & Özel, A. (2024) · Applied Organometallic Chemistry · doi:10.1002/aoc.7643 · Cited by 3
Development of Delivery Systems with Prebiotic and Neuroprotective Potential of Industrial-Grade Cannabis sativa L.
Sip, S., Stasiłowicz-Krzemień, A., Sip, A., Szulc, P. M., Neumann, M., Kryszak, A., & Cielecka‐Piontek, J. (2024) · Molecules · doi:10.3390/molecules29153574 · Cited by 3
Stem Cells as a Novel Source for Regenerative Medicinal Applications in Alzheimer's Disease: An Update
Pandey, K., Srivastava, P., Pandey, S. K., Johari, S., Bhatnagar, P., Sonane, M., & Mishra, A. (2024) · Current Molecular Medicine · doi:10.2174/0115665240334785240913071442 · Cited by 3
Enzymes and Alzheimer's Disease: Pioneering Drug Development Strategies
Godwa, T., Dubey, S., & Tiwari, P. K. (2025) · Current Psychopharmacologye · doi:10.2174/0122115560340307250106065419 · Cited by 3
Evaluating the Neuroprotective and Acetylcholinesterase Inhibitory Properties of Four Calcineurin Inhibitor Drugs: Tacrolimus, Pimecrolimus, Cyclosporin A, and Voclosporin
Koçancı, F. G., Eci̇roglu, H., & Yıldız, F. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05149-0 · Cited by 3
Pharmacogenomics and Psychopharmacology
Lapetina, D. L., Yang, E. H., Henriques, B. C., & Aitchison, K. J. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.007 · Cited by 3
Evaluation of nootropic and neuroprotective properties of Siddha drug Poorana Chandrothaya Chenthuram (PCC) in scopolamine-induced amnesia in mice
Balasubramanian, C., & Ramaswamy, R. (2024) · Phytomedicine Plus · doi:10.1016/j.phyplu.2024.100585 · Cited by 3
Cholinesterase Inhibitory Activity and Molecular Docking Studies of Isocryptolepine‐Triazole Adducts
Tummatorn, J., Meewan, I., Khunnawutmanotham, N., Chimnoi, N., Suwanwong, N., Rodphon, W., Thongsornkleeb, C., Yang, J., & Ruchirawat, S. (2024) · ChemMedChem · doi:10.1002/cmdc.202400447 · Cited by 3
Exploring Cannabis sativa L for Anti-Alzheimer Potential: An extensive Computational Study including Molecular Docking, Molecular Dynamics, and ADMET AssessmentsPreprint
Nour, H., Yamari, I., Abchır, O., Mounadi, N., Samadi, A., Belaıdı, S., & Chtita, S. (2024) · Research Square · doi:10.21203/rs.3.rs-3986384/v1 · Cited by 3
In silico, In vitro, and In vivo Evaluation of the Anti-alzheimer’s Activity of Berberine
Theunis, L. T., Billones, J. B., Hsiao, C., Villaflores, O. B., & Castillo, A. L. (2024) · Current Enzyme Inhibition · doi:10.2174/0115734080306283240719110244 · Cited by 2
Mechanistic Insights into the Neuroprotective Potential of Aegle marmelos (L.) Correa Fruits against Aβ-Induced Cell Toxicity in Human Neuroblastoma SH-SY5Y Cells
Adnan, M., Siddiqui, A. J., Bardakçi, F., Surti, M., Badraoui, R., & Patel, M. B. (2025) · Pharmaceuticals · doi:10.3390/ph18040489 · Cited by 2
A leafy vegetable, Marsilea minuta L.: Review of ethnomedicine, phytochemistry, and pharmacological properties
Yadav, V., Das, S., Mukherjee, S., Khan, A., Mandal, V., Satpathy, S., Goyal, M., & Patra, A. (2025) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2025.100263 · Cited by 2
Association between basal forebrain volume and age in the presenilin‐1 E280A autosomal dominant Alzheimer's disease kindred
He, B., Ospina-Lopera, P., Espinosa, A. C., Becerra, J. C., Osorio, L., Alzate, D., Álvarez, S., Grazia, A., Teipel, S. J., Malotaux, V., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.71052 · Cited by 2
The anti-Alzheimer potential of new spirooxindole derivatives containing 1,4-dihydropyridines as a targeted cholinesterase inhibitor
Pourtaher, H., Mohammadizadeh, M. R., Aliabadi, A., & Iraji, A. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103067 · Cited by 2
Effect of Gladiolus psittascinus Hook bulb supplemented diet on nootropic-related biomolecules in scopolamine-induced cognitive dysfunction rats
Oyetayo, F. L., Akomolafe, S. F., & Ogunlade, A. D. (2023) · Phytomedicine Plus · doi:10.1016/j.phyplu.2023.100425 · Cited by 2
Experimental and pharmacoinformatic approaches unveil the neuropharmacological and analgesic potential of chloroform fraction of Roktoshirinchi (Achyranthes ferruginea Roxb.)
Reza, A. S. M. A., Raihan, R., Azam, S., Shahanewz, M., Nasrin, M. S., Siddique, M. A. B., Uddin, M. N., Dey, A. K., Sadik, G., & Alam, A. K. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.117769 · Cited by 3

Authors: Grossberg, G. T.
Affiliations: Saint Louis University (US)
Corresponding author: Grossberg, George T
ORCID: Grossberg, George T
Venue: Current Therapeutic Research
Publisher: Elsevier BV
Published: 2003-04
Volume: 64
Issue: 4
Pages: 216-235
ISSN: 0011-393X (ISSN-L)
DOI: 10.1016/s0011-393x(03)00059-6
PMC: PMC4052996
OpenAlex: W170237590
Cited by: 384
References: 101
Citations by year: 2026: 26 · 2025: 45 · 2024: 72 · 2023: 41 · 2022: 28 · 2021: 27 · 2020: 20 · 2019: 24 · 2018: 19 · 2017: 14 · 2016: 11 · 2015: 7 · 2014: 3 · 2013: 7 · 2012: 5
FWCI: 3.00
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Current Therapeutic Research (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Novartis Pharma
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: cholinesterase inhibitors, Alzheimer's disease, donepezil, galantamine, rivastigmine, acetylcholinesterase inhibitors, butyrylcholinesterase inhibitors, dose escalation, safety and tolerability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks